TIMING OF TREATMENT WITH ICRF-187--EFFECT ON CHRONIC DOXORUBICIN CARDIOTOXICITY

ICRF-187 治疗时机——对慢性阿霉素心脏毒性的影响

• 批准号: 3757740
• 负责人: V J FERRANS
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3757740
• 关键词: cardiovascular disorder prevention; chemoprevention; chronic disease /disorder; cytotoxicity; doxorubicin; drug administration rate /duration; drug screening /evaluation; medical complication; piperazines

Studies were made of the influence of the timing of the administration of ICRF-187 on the protection exerted by this agent against the cardiac toxicity of doxorubicin. The results obtained show that, for maximal protection, ICRF-187 must be administered either shortly before or simultaneously with doxorubicin.

研究了给药时间的影响 ICRF-187 对该药物对心脏的保护作用 阿霉素的毒性。 所得结果表明，对于最大 保护，ICRF-187 必须在之前或之后不久进行管理 与阿霉素同时使用。